Nilar Tun
New York, NYNPI 1942621263
Payments from drug & device makers
Across 474 payments — averaging $20.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$1K
- Esperion Therapeutics, Inc.$1K
- Amgen$1K
- Novo Nordisk$793
- AstraZeneca$718
- GSK$659
- plus $4K from 25 others
What the payments were for
- Food & beverage$9,716100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 58 | $1,492 |
| Esperion Therapeutics, Inc. | 46 | $1,275 |
| Amgen | 50 | $1,148 |
| Novo Nordisk | 59 | $793 |
| AstraZeneca | 32 | $718 |
| GSK | 34 | $659 |
| AbbVie | 35 | $634 |
| Lilly USA, LLC | 32 | $558 |
| Boehringer Ingelheim | 22 | $429 |
| Sanofi-aventis U.S. LLC | 22 | $359 |
| Merck | 21 | $301 |
| Otsuka America Pharmaceutical, Inc. | 4 | $177 |
| Astellas Pharma US Inc | 9 | $156 |
| Ardelyx, Inc. | 8 | $148 |
| Pfizer | 7 | $125 |
| Intercept Pharmaceuticals, Inc. | 1 | $125 |
| Kowa Pharmaceuticals America, Inc. | 7 | $105 |
| IBSA Pharma Inc. | 5 | $89 |
| Phathom Pharmaceuticals, Inc. | 4 | $85 |
| Radius Health, Inc. | 3 | $58 |
| Bayer | 2 | $57 |
| Hikma Pharmaceuticals USA | 3 | $46 |
| Eyevance Pharmaceuticals LLC | 2 | $31 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $24 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Agios Pharmaceuticals, Inc. | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
| Lupin Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VascepaIcosapent Ethyl | 1,461 | $577,962 |
| JardianceEmpagliflozin | 302 | $240,857 |
| FarxigaDapagliflozin Propanediol | 304 | $215,348 |
| Diclofenac Epolamine | 306 | $214,821 |
| RybelsusSemaglutide | 197 | $214,446 |
| LinzessLinaclotide | 256 | $153,669 |
| ProliaDenosumab | 82 | $137,436 |
| VemlidyTenofovir Alafenamide | 91 | $127,154 |
| SynjardyEmpagliflozin/Metformin Hcl | 170 | $120,381 |
| JanumetSitagliptin Phos/Metformin Hcl | 161 | $113,187 |
| XareltoRivaroxaban | 120 | $84,741 |
| JanuviaSitagliptin Phosphate | 108 | $81,111 |
| EliquisApixaban | 126 | $80,141 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 121 | $77,678 |
| MyrbetriqMirabegron | 109 | $54,454 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy, Synjardy Xr, Tradjenta | $429 | $410,771553 claims |
| AstraZenecaFarxiga, Nexium, Breztri Aerosphere, Bevespi Aerosphere | $718 | $296,848514 claims |
| Novo NordiskRybelsus, Ozempic | $793 | $246,281231 claims |
| AbbVieLinzess, Namzaric, Creon, Restasis | $634 | $240,023383 claims |
| MerckJanumet, Januvia, Janumet Xr | $301 | $210,655287 claims |
| AmgenProlia, Evenity (2 Syringes) | $1,148 | $170,47796 claims |
| GileadVemlidy | $1,492 | $127,15491 claims |
| PfizerEliquis | $125 | $80,141126 claims |
| GSKTrelegy Ellipta | $659 | $77,678121 claims |
| Astellas Pharma US IncMyrbetriq | $156 | $54,454109 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $1,275 | $37,22685 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $177 | $15,14911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in New Yorkon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.